APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 George LauShuntaro ObiMasao Omata Guidelines 21 November 2024 Pages: 1661 - 1683
Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management Akash ShuklaDon C. RockeyShiv Kumar Sarin Guidelines 15 November 2024 Pages: 1684 - 1711
Rechallenge with immune checkpoint inhibitors therapy for patients with HCC-lot more to learn George Lau Editorial 20 November 2024 Pages: 1712 - 1714
Dynamic role of exosomal long non-coding RNA in liver diseases: pathogenesis and diagnostic aspects Mohammed IsmailMissaa M. FadulLixin Sun Review Article 21 September 2024 Pages: 1715 - 1730
Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD Mingqian JiangZiyan PanMohammed Eslam Original Article 28 August 2024 Pages: 1731 - 1739
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research Maito SuohSaeed EsmailiJacob George Original Article Open access 16 October 2024 Pages: 1740 - 1755
Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study Yuxin LinPingping Lifor the CRDS Study Investigators Original Article 02 May 2024 Pages: 1756 - 1769
Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics Nan ZhangZhaohui LiHanping Wang Original Article Open access 02 July 2024 Pages: 1770 - 1780
Mesenchymal stem cells-derived exosomes alleviate liver fibrosis by targeting Hedgehog/SMO signaling Ruobin ZongYan ZhengChangyong Li Original Article 13 August 2024 Pages: 1781 - 1791
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer Dongming LiuWenshuai ChenHua Guo Original Article Open access 10 August 2024 Pages: 1792 - 1803
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy Kuan-Chang LaiYen-Hao ChenSan-Chi Chen Original Article Open access 23 November 2024 Pages: 1804 - 1814
Is laparoscopic hepatectomy superior to radiofrequency ablation in treating small hepatocellular carcinoma? Dali XiongJiaran LiShuanghu Yuan Letter to the Editor 27 August 2024 Pages: 1815 - 1816
Letter to the editor to ‘‘Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases’’ Bihua YaoJianguo Wu Letter to the Editor 29 August 2024 Pages: 1817 - 1818
Who better identifies significant liver fibrosis, MAFLD or MASLD, needs more rigorous, in-depth study Haoxuan ZouXiaobin Sun Letter to the Editor 24 September 2024 Pages: 1819 - 1820
